News & Insights

Citeline’s Scrip provides access to business-critical market and commercial intelligence from a global network of analysts, journalists and key opinion leaders. Scrip delivers analysis, news and insights across multiple therapy areas and product types with end-to-end coverage from drug discovery to development, market launch and finance/dealmaking.

Citeline’s In Vivo delivers comprehensive analysis and strategic insights for life science decision-makers, with interviews and exclusive insight from key players in the pharma, medtech and diagnostics industries, to inform corporate strategies and commercial activities. In Vivo’s in-depth analysis spans influential deals, R&D, commercial, financial and market access strategies and trends.

Since 1939, Citeline’s Pink Sheet has been the leader in providing business-critical insights on pharmaceutical news, and analysis of regulatory policies and trends. Our global team of more than 20 journalists tracks marketing application progress from submission to approval, covering biosimilars, generics, brand name/innovator drugs and more.

Citeline’s Medtech Insight offers access to global developments in the medical technology sector, including surgical, orthopedic, cardiovascular and other markets. More than a dozen experienced journalists and analysts based in Europe, US and Asia cover product news, investment trends, M&A activity, regulatory changes, policy issues and more.

A trusted industry source since 2003, Citeline’s Generics Bulletin delivers in-depth news and analysis on the latest regulatory, legal, market and commercial developments in the global generics, biosimilars and value-added medicines industries. There’s nothing generic about it; our broad network of global expert analysts and journalists provide in-depth coverage, from competitive intel and M&As to new product launches, manufacturing updates, marketing challenges, advertising strategies and more.

Citeline’s HBW Insight is the single source of regulatory, legislative and commercial news and insight for the health, beauty & wellness consumer sectors, including the OTC, dietary supplement and cosmetic markets.

Citeline's Chemist+Druggist has been informing, supporting and championing community pharmacy since 1859. With a reputation as the leading source of news, commentary and analysis for the UK community pharmacy industry, Chemist+Druggist (C+D) is renowned for its exclusive stories and ground-breaking investigations into the most pressing issues affecting the sector.